Form 4: RIGL CFO Exercises Options, Adjusts Holdings

Rigel Pharmaceuticals' EVP & CFO, Dean L. Schorno, exercised stock options and adjusted common stock holdings, reflecting a recent reverse stock split.

Summary

• Dean L. Schorno, Executive Vice President and Chief Financial Officer of Rigel Pharmaceuticals Inc. (RIGL), reported transactions on June 1, 2026.
• Schorno acquired 1,200 shares of common stock by exercising an employee stock option at a price of $18.7 per share.
• An additional 2,181 shares of common stock were acquired through the exercise of another employee stock option at $12.7 per share; these numbers are adjusted for a one-for-ten reverse stock split effective June 27, 2024.
• Schorno disposed of 928 shares of common stock at a price of $29.86, likely to cover tax obligations or exercise costs.
• Following these transactions, Schorno directly beneficially owns 78,790 shares of common stock.
• Remaining derivative holdings include 9,632 employee stock options with an exercise price of $18.7 and 13,518 employee stock options with an exercise price of $12.7.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine insider transaction where the CFO exercised vested stock options, partially offsetting with a disposition likely for tax purposes. The adjustment for a reverse stock split is a factual update.

Positives

• The CFO exercised stock options, which can be interpreted as a signal of confidence in the company's future performance and stock appreciation.

Negatives

• A portion of shares (928) was disposed of, likely to cover tax liabilities or the cost of exercising options, which is a routine but not value-additive transaction.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, such as option exercises, are common in the biotechnology and pharmaceutical sectors as part of executive compensation packages. The reverse stock split, which adjusted the share numbers and prices in this filing, indicates a corporate action to potentially increase share price and meet listing requirements, a trend seen in some smaller-cap biotech firms.

Stakeholder Impact

• Shareholders: Provides transparency into executive stock ownership and transactions, which can offer insights into management's alignment with shareholder interests.

Next Steps

• Continued vesting of remaining employee stock options according to their respective schedules.

Key Dates

Recommendation

This Form 4 details a routine insider transaction where the CFO exercised vested stock options and disposed of a portion of shares, likely for tax purposes. While option exercises can signal insider confidence, this specific transaction is not substantial enough to warrant a change in investment recommendation based solely on this filing. Investors should consider broader company fundamentals and market conditions.

Keywords

RIGL, Rigel Pharmaceuticals, Dean L. Schorno, Form 4, insider trading, stock options, executive compensation, common stock, reverse stock split